Company: TAK
Filing Date: 2025-07-30
Form Type: 6-K
Source: 0001395064-25-000120
Chunk: 6

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-07-30
Form: 6-K
Chunk 6
---
 % |     |     |   1.7 | %                         |
| Oncology      |     |           |   142.1 |     |            |   138.8 |     |          |   -3.3 |     |          |  -2.3 | % |     |     |   1.8 | %                         |
| Vaccines      |     |           |    12.5 |     |            |    11.5 |     |          |   -1.1 |     |          |  -8.4 | % |     |     |  -6.2 | %                         |
| Neuroscience  |     |           |   169.1 |     |            |   108.6 |     |          |  -60.4 |     |          | -35.7 | % |     |     | -32.6 | %                         |
| Other         |     |           |    64.9 |     |            |    51.2 |     |          |  -13.7 |     |          | -21.1 | % |     |     | -18.0 | %                         |
| Total         |     |           | 1,208.0 |     |            | 1,106.7 |     |          | -101.3 |     |          |  -8.4 | % |     |     |  -3.7 | %                         |

Year-on-year change in revenue for this three-month period in each of our business areas was primarily attributable to the following products:

#### GI
In GI, revenue was JPY 339.3 billion (JPY -9.2 billion and -2.6% AER, +2.6% CER).

Sales of DEXILANT (for acid reflux disease) were JPY 8.3 billion (JPY -3.5 billion and -29.7% AER, -22.4% CER). The decrease was primarily due to the impact of multiple generic entrants in Canada, accompanied by unfavorable foreign exchange rates.

Sales of RESOLOR/MOTEGRITY (for chronic idiopathic constipation) were JPY 2.2 billion (JPY -3.3 billion and -60.5% AER, -58.2% CER). The decrease was primarily due to the impact of multiple generic entrants in the U.S. beginning in January